Pipeline

Essential Tremor

Essential tremor is one of the most common movement disorders, with an estimated 7 million people living with essential tremor in the U.S. alone. It affects approximately 5% of adults aged 65 or older. Essential tremor begins gradually, often affecting the upper limbs (but can affect the head, voice, and legs), and commonly runs in families. It involves involuntary and rhythmic shaking of the limbs and other body parts during movement that can impact activities of daily living, including eating, drinking, writing, and dressing. Essential tremor may be mistaken for tremor in Parkinson’s disease, and can be aggravated by emotional stress, fatigue, or substances like caffeine.

Beta-blockers or anti-seizure medications are often used to treat essential tremor. However, many patients become resistant to these therapies over time. The only approved medication for essential tremor was approved in the 1970s.

NBI-827104: An Investigational Therapy for Essential Tremor

NBI-827104 is an investigational, potent, selective, orally active, and brain penetrating T-type calcium channel blocker.

Neurocrine Biosciences acquired the exclusive rights to NBI-827104 from Idorsia Ltd.

Neurocrine Biosciences is also developing NBI-827104 for the potential treatment of Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep (EE-CSWS).

Clinical Trials: Essential Tremor

Neurocrine Biosciences is conducting a Phase 2, randomized, double-blind placebo-controlled, crossover study to assess the safety, tolerability, pharmacokinetics, and efficacy of NBI-827104 in adult patients with essential tremor in the Netherlands. For more information about this Phase 2 study of NBI-827104, please visit clinicaltrials.gov.